Work

Q-TWiST analysis of tivozanib (T) versus sorafenib (S) in patients with advanced renal cell carcinoma (RCC) in the TIVO-3 study.

Year: 2021

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2021.39.6_suppl.298

Authors: Michael Szarek, Michael N. Needle, Brian I. Rini, Sumanta K. Pal, David F. McDermott, Michael B. Atkins, Thomas E. Hutson, Bernard Escudier

Institutions: SUNY Downstate Health Sciences University, AVEO Oncology (United States), Vanderbilt University, Vanderbilt-Ingram Cancer Center, City Of Hope National Medical Center, City of Hope, Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center, Georgetown University Medical Center, Georgetown Lombardi Comprehensive Cancer Center, Texas A&M University, Institut Gustave Roussy

Language: English

Topic: Health Systems, Economic Evaluations, Quality of Life

Subfield: Economics and Econometrics

Field: Economics, Econometrics and Finance

Domain: Social Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4243017995

Cites:

Cited by:

Related to: 10